Varonis to Present at the Susquehanna Technology Conference
Mar 06, 2018 21:05 pm UTC| Business
NEW YORK, March 06, 2018 -- Varonis Systems, Inc. (NASDAQ:VRNS), a pioneer in data security and analytics, today announced its participation at the Susquehanna Technology Conference in New York City. The presentation...
Horizon Pharma plc Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Mar 06, 2018 21:05 pm UTC| Business
DUBLIN, Ireland, March 06, 2018 -- Horizon Pharma plc (NASDAQ:HZNP) today announced that the compensation committee of its board of directors approved the grant on Mar. 1, 2018 of inducement restricted stock units for...
Depomed to Present at Healthcare Conferences in March
Mar 06, 2018 21:04 pm UTC| Business
NEWARK, Calif., March 06, 2018 -- Depomed, Inc. (NASDAQ:DEPO) today announced that members of senior management will participate in fireside chats at the following healthcare conferences during the month of March. ...
Sunrun Reports Fourth Quarter and Full Year 2017 Financial Results
Mar 06, 2018 21:02 pm UTC| Business
Unlevered NPV of $1.22 per watt in Q4 2017, the highest in the company’s history Total deployments of 323 MWs in 2017, an increase of 15% year-over-year Net Earning Assets of $1.2 billion, an increase of 16%...
Mar 06, 2018 21:02 pm UTC| Business
Date: Friday, March 9, 2018Time: 9:00 a.m. (Eastern Time) BETHESDA, Md., March 06, 2018 -- You are invited to participate in TerraForm Power's (Nasdaq:TERP) 2017 Fourth Quarter and Full Year Webcast and Conference...
Zogenix Provides Corporate Update and Reports Fourth Quarter and Full-Year 2017 Financial Results
Mar 06, 2018 21:01 pm UTC| Business
ZX008 Granted Breakthrough Therapy Designation in Dravet syndrome by FDALast patient randomized into second Phase 3 clinical trial of ZX008 in patients with Dravet syndrome, Study 1504Initiated global Phase 3 clinical...
Mar 06, 2018 21:01 pm UTC| Business
Completed dosing of third cohort in RGX-314 Phase I clinical trial for wet AMDContinuing dosing of second cohort in RGX-501 Phase I/II clinical trial for HoFHAnticipate presenting topline data from RGX-314 and RGX-501...